Venetoclax and Irinotecan in Relapsed/Refractory SCLC
Status:
Withdrawn
Trial end date:
2028-06-30
Target enrollment:
Participant gender:
Summary
This study is a single-arm, open-label, multicenter phase 1/2 trial designed to establish the
recommended phase 2 dose (RP2D) of daily oral venetoclax when given in combination with
irinotecan in patients with relapsed or refractory small cell lung cancer (SCLC).